Werkgroep Cardiologische centra Nederland

BEST (Follow-up)

A double blind placebo controlled study to evaluate the effects of bexagliflozin on hemoglobin A1c in patients with type 2 diabetes and increased risk of cardiovascular adverse events
Medicine
bexagliflozin
Population
Diabetes mellitus
Phase
III
Starting year
2015
More information
ClinivalTrials.gov

Director of Study

dr. A.F.M. Kuijper (Cardioloog)
Haarlem, Spaarne Gasthuis